SUMMARY AND CONCLUSION

Summary
Infections caused by bacteria have been the major cause of disease throughout the human population. Wide use of antibiotics in the treatment of bacterial infections has led to the emergence and spread of multidrug resistant strains of microbes and is becoming a major threat to public health in the 21 st century. Antibiotic resistance in Staphylococcus aureus has become a serious problem because of its ability to acquire resistance against the currently used antimicrobials. Drug resistance due to NorA efflux pump is primary defense mechanism developed by S. aureus. Inhibition of NorA efflux pump may potentially improve the clinical efficacy of existing antibiotics. Efflux pump inhibition can be achieved by developing resistance modifying agents or efflux pump inhibitors. Drug synergism between known antibiotics and bioactive plant extracts is a novel and beneficial concept. The present study was therefore done to restore activity of antimicrobials against S. aureus by evaluating the combination of medicinal plant extracts with antibiotics.
The aim of the present study was isolation and characterization of EPI agents of S. aureus from medicinal plants of Western Himalayas. The findings of the study are summarized below:
Confirmation of S. aureus strains
For the current study, three S. aureus (2378 NorA over-expressive, 8325-4 wild type, 1758 NorA knockout) strains were procured from Northeastern University, Boston and were confirmed by growing on selective media, Gram's staining and standard biochemical testing. No phenotypic changes were observed in the procured strains.
Cartwheel assay for efflux pump presence
EtBr-agar cartwheel assay was performed for the confirmation of presence of efflux pump among all the strains of S. aureus (2378 NorA over-expressive, 8325-4 wild type, 1758 NorA knockout). It was observed that 2378 NorA over-expressive strain had maximum efflux activity than 8325-4 wild type strain. Least or no efflux activity was observed for 1758 NorA knockout strain. 
Synergistic activity of plant extracts and antibiotics
In the present study, methanolic and ethyl acetate extracts of selected medicinal plants showed maximum synergistic activities with antibiotics (ciprofloxacin and norfloxacin), while aqueous extracts did not showed any synergistic activity against S. aureus strains. This might be due to the variation in sensitivity of different extracts to extraction procedures and evaporation temperature. Maximum plants showed synergistic activity, but results were varied for all the three strains of S. aureus. Maximum synergism by increase in zone size by 7 mm in methanolic extract with ciprofloxacin was observed against 2378 NorA over-expressive strain, followed by 
Screening of efflux pump inhibitory activity
On the basis of synergistic activity to inhibit the NorA efflux pump of S. aureus, 12 plants showing maximum synergistic activity were further screened for efflux pump inhibitory activity by berberine uptake assay and ethidium bromide efflux inhibition assay. In berberine uptake assay, reduction in MIC value of berberine was dependent on the tested strains. Maximum Phytochemical analysis revealed the presence of carbohydrates, reducing sugars, glycosides, amino acids, proteins, terpenoids, tannins, phenolics, flavonoids and saponins in the root extract of Angelica glauca (ME). In root extract of Heracleum lanatum (ME), the major phytoconstituents present were carbohydrates, reducing sugars, glycosides, amino acids, proteins, steroids, terpenoids, tannins, phenolics, flavonoids, alkaloids and saponins.
Bioassay guided fractionation of the extracts yielded six fractions each for metanolic extract of Angelica glauca and Heracleum lanatum. EtBr efflux inhibition assay was performed for separated fractions and acetone fraction of methanolic root extract of Angelica glauca was found to be most potent EPI.
In silica gel thin layer chromatography of acetone fraction of Angelica glauca, chloroform: methanol (9:1) mobile phase showed best separation of compounds present in acetone fraction.
Compounds present in bioactive acetone fraction were further identified by LC/MS and major compounds were trans-stilbene, ferulic acid, N-(3-acetamidophenyl)-2-(4-fluoro-Nmethylsulfonylanilino)acetamide, [(2R, 5R)-4-(4-bromobenzoyl)-2,5-dimethylpiperazin-1-yl]-(4-
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Summary and conclusion Faculty of Applied Sciences and Biotechnology 107 bromophenyl)methanone,6-sopropyl-2-(4-(piperidin-1-ylsulfonyl)benzamido)-4,5,6,7-tetrahydro thieno [2,3-c]pyridine-3-carboxamide hydrochloride and dioxathion.
Silica gel column chromatography of bioactive acetone fraction of Angelica glauca yielded 26 fractions and each fraction was evaluated for efflux pump inhibitory activity by EtBr efflux inhibition assay. Fraction no. 10 showed maximum efflux pump inhibitory activity against S. aureus strains and hence subjected for identification of efflux pump inhibitory activity Silica gel TLC analysis of bioactive fraction no 10 revealed the presence of single band with R f value of 0.5. LC-MS of bioactive fraction no 10 identified the phytocompound as 4-Hydroxy-3methoxycinnamic acid (ferulic acid).
Synergistic effect of ferulic acid with antimicobials (Ciprofloxacin, Norfloxacin, Cetrimide)
Synergistic activity of ferulic acid with ciprofloxacin showed 8-fold and 4-fold reduction in the MIC against 2378 NorA over-expressive strain and 8325-4 wild type strain respectively. No reduction in MIC was observed against 1758 NorA knockout strain. Synergistic activity of ferulic acid with norfloxacin and cetrimide showed 4-fold reduction in the MIC against 2378
NorA over-expressive strain and 8325-4 wild type strain. Reduction in MIC was also found against 1758 NorA knockout. Fractional inhibitory concentration index revealed that the ciprofloxacin, norfloxacin and cetrimide with ferulic acid were synergistic against 2378 overexpressive and 8325-4 wild type strains, while no interaction was observed against 1758 NorA knockout strain.
Conclusion
For treatment of infectious diseases, the synergistic effect from the combination of antibiotic with plant extracts against resistant bacteria leads to new choices by enhancing the antimicrobial activity of existing antibiotics. This study has shown that crude methanolic extract of the roots of revealed ferulic acid as a potent EPI in the present study. Ferulic acid showed synergism with ciprofloxacin, norfloxacin and cetrimide against 2378 NorA over-expressive and 8325-4 wild type strain, while no synergism was observed against 1758 NorA knockout strain demonstrating that the synergism is NorA multidrug pump dependent and ferulic acid as potent efflux pump inhibitor of NorA multidrug efflux pump. Hence, ferulic acid may be used as a future molecule for NorA efflux pump inhibition in combination with antibiotics for curing infections caused by multidrug resistant strains of S. aureus. Previously reported efflux pump inhibitors against S. aureus were found toxic at the required concentrations, but reports have shown that ferulic acid has low toxicity and have many pharmacological properties. Therefore ferulic acid could become a future molecule to counteract the MDR caused by activation of NorA efflux pump in S. aureus.
Further effort to evaluate toxicity profiling in a broad spectrum seems reasonable. The future challenge is to study the effect of this formulation in vivo mouse model system.
